rethinkPeptides Search
Menu
Study breakdown

Seizures Trigger a Surge-Then-Rebound Pattern in Brain Opioid Peptides

ReviewPreliminary evidence
The takeaway

Seizures consistently cause an initial drop in hippocampal opioid peptides (from release) followed by overproduction — dynorphin changes are larger and may be anticonvulsant.

Deplete-then-overproduce

Consistent pattern across electroshock, kainic acid, and kindling seizure models

What the researchers found

After seizures (from electroshock, kainic acid, or kindling), both dynorphin and enkephalin initially decrease in the hippocampus, indicating release. But their recovery patterns differ dramatically.

Enkephalin shows a rapid, sustained rebound above normal levels after all three seizure types. Dynorphin shows a large, sustained decrease after electroshock and kindling, with slow recovery.

Mu-opioid receptor antagonists shortened the kindling process (where repeated mild stimulation eventually produces seizures). This strongly suggests brain opioid peptides are involved in how seizure susceptibility develops.

Enkephalin in the hippocampus appears to mediate wet-dog shakes (a specific seizure behavior seen in rodents), connecting it to the opioid withdrawal syndrome.

Why it matters

Understanding how seizures affect the brain's opioid system matters for epilepsy treatment. If opioid peptides modulate seizure threshold and seizure-related behaviors, targeting opioid receptors could be a new approach to epilepsy management.

How the study worked

Review of the authors' own experimental work using electroconvulsive shock, kainic acid injection, and amygdaloid kindling in rats. Opioid peptide levels measured by immunoassay. Functional role tested with opioid antagonists and antisera.

What this study cannot tell us

Review of primarily the authors' own work. Results are from rats and may not apply to human epilepsy. The hippocampus was the main focus; other brain regions were less studied.

How to read the evidence

Preliminary — review of animal studies proposing a mechanistic framework.

When this study was published

Published in 1988 — influential review shaping the opioid-epilepsy research field.

The bigger picture

The brain has built-in anti-seizure mechanisms using endogenous opioid peptides. Harnessing this natural protection could lead to new epilepsy treatments.

Questions still open

  • Could dynorphin supplementation prevent epilepsy progression?
  • Does the rebound mechanism fail in drug-resistant epilepsy?

Common questions

Are opioid peptides anticonvulsant?
Dynorphin appears to be — it is released during seizures and may help terminate seizure activity. Enkephalins are less clear and may have both pro- and anti-convulsant properties depending on the receptor activated.
Could this lead to new epilepsy drugs?
Possibly. Drugs that enhance dynorphin signaling or mimic its anticonvulsant effects could complement existing epilepsy medications.

Read the original research

Seizure-induced alterations in the metabolism of hippocampal opioid peptides suggest opioid modulation of seizure-related behaviors.

NIDA research monograph, 82, 48-66

Citation

Hong, J S; McGinty, J F; Grimes, L; Kanamatsu, T; Obie, J; Mitchell, C L. (1988). Seizure-induced alterations in the metabolism of hippocampal opioid peptides suggest opioid modulation of seizure-related behaviors.. NIDA research monograph, 82, 48-66.